New York, Feb 23, 2026, 07:31 EST — Premarket
- KVUE edged up roughly 0.5% in premarket action, following Friday’s close at $18.63.
- Kimberly-Clark’s offer values Kenvue at roughly $19.44 a share, based on KMB’s current share price. KVUE is still trading under that implied deal price.
- The U.S. antitrust waiting period has now lapsed, according to a recent filing. Investors are turning their attention to overseas regulatory sign-offs and eyeing restructuring costs set for 2026.
Kenvue Inc edged up 9 cents, a gain of roughly 0.5%, to $18.72 ahead of the bell Monday. The stock last closed at $18.63 on Friday.
Kimberly-Clark will pick up the consumer health outfit in a cash-and-stock transaction first unveiled in November. Each Kenvue share fetches $3.50 in cash and 0.14625 shares of Kimberly-Clark—working out to roughly $19.44 a share, based on Kimberly-Clark’s premarket quote of $109.02.
Kenvue is now sitting around 4% below the offer price, a gap merger traders watch for hints on timing and perceived deal risk. Kimberly-Clark moved up about 0.3% early Monday.
The filing indicated the Hart-Scott-Rodino waiting period—essentially the U.S. antitrust timer for large mergers—ran out on Feb. 4. Still on the table: multiple foreign regulators haven’t signed off yet, according to the same filing.
Last week, Kenvue posted fourth-quarter numbers that topped expectations, and at the same time revealed plans to cut around 770 jobs—roughly 3.5% of its staff. The company put pre-tax restructuring and related costs at about $250 million for 2026, all linked to the layoffs.
Chief Executive Kirk Perry kept his tone measured on the tie-up, though the company flagged incoming restructuring. “We ended 2025 with stronger top- and bottom-line performance in the fourth quarter,” Perry said in a statement. Kenvue Investors
Kenvue is skipping its customary quarterly conference call this time, citing the pending deal. The company flagged the change earlier this month and plans no live discussion of results.
Stocks opened higher. The S&P 500 ETF added close to 0.7% early on, while the consumer staples sector ETF ticked up around 0.2%.
Kenvue, behind brands like Tylenol, Band-Aid, Listerine, Neutrogena, and Aveeno, claims its products are used by roughly 1.2 billion people worldwide.
But the numbers don’t always hold steady. A stumble in foreign approvals or a dip in Kimberly-Clark shares might push the gap wider — and trimming expenses risks backfiring, especially if it hits supply lines or weakens brand backing.
Investors mark Feb. 25 for Kenvue’s upcoming $0.2075 per-share quarterly dividend. After that, attention shifts to the next regulatory ruling—whether it speeds up or slows down the deal’s progress.
